pretickt

Is MCK a good stock to buy?

McKesson Corporation · end-of-day data as of Nov 13, 2026

McKesson
MCK · $127B
$1,102.81+2.4%
Nov 13, 2026 · close
$900$1000$1100SepOctNov9:3016:003 months +27.0%Nov 13 · close
▲ 6
  • ConsensusBuy · 16
  • P/E vs sector-12.0%
  • FCF yield+5.4%
  • MAs4 of 4
  • MACD4.90
  • Sector▲ +15.9%
Neutral
  • Earnings in82d
  • P/E28.4x
  • Support-13.0%
  • Off 52w high-1.7%
  • Volume0.7x
  • Bollingerupper half
  • Trendsideways
  • 52w range$724–$1,122
  • ATR+2.3%
  • Off ATH-1.7%
▼ 5
  • PT$994.44 -9.8%
  • P/E vs own+28.5%
  • Insiders-$2.24M
  • News
  • RSI75

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is McKesson a good stock to buy?

McKesson is strong on 4 of the 5 questions about the business. The price is high: 28.4 times its earnings, above its 3-year median of 24.0 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand growing
  2. Advantage some edge
  3. Economics profits growing
  4. Execution delivers
  5. Fragility sturdy
  6. Price expensive
DemandDo people want more of what it sells?growing

MCK sales growth revenue growth

+13%a year, for the last 3 years

McKesson's sales grew 13% a year for 3 years, to $403B in fiscal 2026.

MCK analysts' forecast revenue estimates

+8%the sales they expect next fiscal year, on the last

Analysts expect McKesson's sales to grow 8% to $435B in fiscal 2027 (12 analysts).

MCK peers

pretickt analysis+8%its sales in 12 months, on a year before

McKesson's sales grew 8% in the 12 months to Sep 30, 2026, faster than Henry Schein (+6%), Cencora (+5%) and Bristol-Myers Squibb (+4%), slower than Cardinal Health (+10%).

MCK sales by business revenue by segment

84%of its sales from North American Pharmaceutical

North American Pharmaceutical brought McKesson 84% of its sales in fiscal 2026; Oncology And Multispecialty 12%.

Advantage moatIs it hard to copy?some edge

MCK margin on each sale gross margin

4%left after making the product

McKesson kept 4% of each sale after making the product in the 12 months to Sep 30, 2026; its peers' median is 17%.

EconomicsDoes it make good money?profits growing

MCK profit per share

+49%in its last fiscal year

McKesson's earnings per share grew 49% in fiscal 2026, to $38.47.

ExecutionDoes it deliver what it promises?delivers

MCK earnings vs estimates

7 of 8quarters above the analysts' estimate

McKesson beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Nov 4, 2026.

MCK insider selling

-$30.13Msold, net, by its executives in 12 months

McKesson's executives and directors sold a net $30.13M of shares in the 12 months to Nov 13, 2026; none bought.

MCK number of employees

-4%fewer people in a year

McKesson had 43,000 employees at the end of fiscal 2026, 4% fewer than a year before.

MCK CEO pay

$24.21Mfor fiscal 2026, 71% of it in stock and options

McKesson paid its CEO $24.21M for fiscal 2026, 71% of it in stock and options.

Fragility risksCould something break it?sturdy

MCK financial health Altman Z-score

5.8Altman Z-score, safe above 3

McKesson's Altman Z-score is 5.8 (Nov 13, 2026), above 3, where the safe zone starts.

MCK quality checks Piotroski score

7 of 9checks passed

McKesson passes 7 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on long-term debt and sales for its assets.

MCK biggest customers

45%of sales from its 3 biggest customers

CVS made 45% of McKesson's sales in fiscal 2026.

MCK shareholders institutional ownership

pretickt analysis
  • BlackRock9.1% ▼
  • Vanguard9.0% ▼
  • State Street4.7% ▼
2,089institutions hold it; the largest sold shares

2,089 institutions hold 87% of McKesson's shares (Jun 30, 2026); BlackRock, Vanguard and State Street sold some.

MCK in past recessions

pretickt analysis+2%its sales in the worst one

McKesson's sales grew through each of the last 2 US recessions (2008–09 and 2020).

Price valuationIs the price reasonable?expensive

MCK price vs profit P/E ratio

28.4×a year's earnings

McKesson's P/E ratio is 28.4 (Nov 13, 2026), above its 3-year median of 24.0.

MCK price vs peers

pretickt analysis28.4×a year's earnings, against its peers

Investors pay 28.4 times McKesson's earnings (Nov 13, 2026), more than for Henry Schein (23.6), Cencora (20.0) and Bristol-Myers Squibb (14.1), less than for Cardinal Health (36.4).

MCK analysts' target price target

-10%to their average target

Analysts' average price target for McKesson is $994, 10% below the Nov 13, 2026 close of $1,102.81.

What is McKesson's P/E ratio?

McKesson's P/E ratio is 28.4 (Nov 13, 2026), above its 3-year median of 24.0. Investors pay 28.4 times McKesson's earnings (Nov 13, 2026), more than for Henry Schein (23.6), Cencora (20.0) and Bristol-Myers Squibb (14.1), less than for Cardinal Health (36.4).

Are insiders selling McKesson stock?

McKesson's executives and directors sold a net $30.13M of shares in the 12 months to Nov 13, 2026; none bought.

How does McKesson make money?

North American Pharmaceutical brought McKesson 84% of its sales in fiscal 2026; Oncology And Multispecialty 12%.

Who owns McKesson stock?

2,089 institutions hold 87% of McKesson's shares (Jun 30, 2026); BlackRock, Vanguard and State Street sold some.

How many employees does McKesson have?

McKesson had 43,000 employees at the end of fiscal 2026, 4% fewer than a year before.

Who are McKesson's biggest customers?

CVS made 45% of McKesson's sales in fiscal 2026.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.